Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy
Bassel Nazha, Manoj K. Mishra, Rebecca D. Pentz, et al.
American Society of Clinical Oncology Educational Book (2019), Iss. 39, pp. 3-10
Closed Access | Times Cited: 222

Showing 1-25 of 222 citing articles:

Cancer statistics for African American/Black People 2022
Angela N. Giaquinto, Kimberly D. Miller, Katherine Y. Tossas, et al.
CA A Cancer Journal for Clinicians (2022) Vol. 72, Iss. 3, pp. 202-229
Open Access | Times Cited: 467
Digitizing clinical trials
Omer T. Inan, Pamela Tenaerts, Sheila A. Prindiville, et al.
npj Digital Medicine (2020) Vol. 3, Iss. 1
Open Access | Times Cited: 281
Race/ethnicity reporting and representation in US clinical trials: A cohort study
Brandon E. Turner, Jecca R. Steinberg, Brannon T. Weeks, et al.
The Lancet Regional Health - Americas (2022) Vol. 11, pp. 100252-100252
Open Access | Times Cited: 272
Priorities for cancer research in low- and middle-income countries: a global perspective
C.S. Pramesh, Rajendra Badwe, Nirmala Bhoo‐Pathy, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 649-657
Open Access | Times Cited: 270
Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement
Randall A. Oyer, Patricia A. Hurley, Leigh Boehmer, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 19, pp. 2163-2171
Closed Access | Times Cited: 154
Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion
Noah Goodson, Paul Wicks, Jayne Morgan, et al.
npj Digital Medicine (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 89
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
Amin H. Nassar, Elio Adib, Sarah Abou Alaiwi, et al.
Cancer Cell (2022) Vol. 40, Iss. 10, pp. 1161-1172.e5
Open Access | Times Cited: 87
The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Christoph U. Correll, Marco Solmi, Samuele Cortese, et al.
World Psychiatry (2023) Vol. 22, Iss. 1, pp. 48-74
Open Access | Times Cited: 83
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
Sandeep M. Nayak, Hillary Jackson, Nathan D. Sepeda, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 48
Cancer statistics for African American and Black people, 2025
Abdulrasaki Saka, Angela N. Giaquinto, Lauren E. McCullough, et al.
CA A Cancer Journal for Clinicians (2025)
Open Access | Times Cited: 2
Community-Based Participatory Research (CBPR) to Enhance Participation of Racial/Ethnic Minorities in Clinical Trials: A 10-Year Systematic Review
Soroya Julian McFarlane, Aurora Occa, Wei Peng, et al.
Health Communication (2021) Vol. 37, Iss. 9, pp. 1075-1092
Closed Access | Times Cited: 90
Evidence Gaps in Cancer Survivorship Care: A Report From the 2019 National Cancer Institute Cancer Survivorship Workshop
Lisa Gallicchio, Emily S. Tonorezos, Janet S. de Moor, et al.
JNCI Journal of the National Cancer Institute (2021) Vol. 113, Iss. 9, pp. 1136-1142
Open Access | Times Cited: 88
Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies
Joseph M. Unger, Dawn L. Hershman, Raymond U. Osarogiagbon, et al.
JNCI Cancer Spectrum (2020) Vol. 4, Iss. 4
Open Access | Times Cited: 81
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Luciano J. Costa, Faith E. Davies, Gregory Monohan, et al.
Blood Advances (2021) Vol. 5, Iss. 19, pp. 3748-3759
Open Access | Times Cited: 64
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials
Ryan Huey, Goldy C. George, Penny Phillips, et al.
The Oncologist (2021) Vol. 26, Iss. 7, pp. 588-596
Open Access | Times Cited: 64
Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment
Johannes Thrul, Albert Garcia‐Romeu
Drugs Education Prevention and Policy (2021) Vol. 28, Iss. 3, pp. 211-214
Open Access | Times Cited: 63
Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials
Karen Allison, Deepkumar Patel, Leah Greene
JAMA Network Open (2021) Vol. 4, Iss. 5, pp. e218348-e218348
Open Access | Times Cited: 61
Disparities in Pediatric Oncology: The 21st Century Opportunity to Improve Outcomes for Children and Adolescents With Cancer
Paula Aristizabal, Lena E. Winestone, Puja J. Umaretiya, et al.
American Society of Clinical Oncology Educational Book (2021), Iss. 41, pp. e315-e326
Open Access | Times Cited: 61
Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes
Raymond U. Osarogiagbon, Helmneh M. Sineshaw, Joseph M. Unger, et al.
American Society of Clinical Oncology Educational Book (2021), Iss. 41, pp. 66-78
Open Access | Times Cited: 59
Cancer healthcare disparities among African Americans in the United States
Edith Mitchell, Olatunji B. Alese, Clayton Yates, et al.
Journal of the National Medical Association (2022) Vol. 114, Iss. 3, pp. 236-250
Closed Access | Times Cited: 41
Towards equitable AI in oncology
Vidya Sankar Viswanathan, Vani Parmar, Anant Madabhushi
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 628-637
Closed Access | Times Cited: 12
Factors Associated With Racial and Ethnic Disparities in Locally Advanced Rectal Cancer Outcomes
Rebecca M. Shulman, Mengying Deng, Elizabeth A. Handorf, et al.
JAMA Network Open (2024) Vol. 7, Iss. 2, pp. e240044-e240044
Open Access | Times Cited: 9
Investigator racial diversity and clinical trial participation
Marcella Alsan, Romaine Campbell, Lukas Leister, et al.
Journal of Health Economics (2025) Vol. 100, pp. 102968-102968
Closed Access | Times Cited: 1
The missing data: A review of gender and sex disparities in research
Bhavana Pothuri, L Guevara, B.J. Rimel, et al.
Cancer (2025) Vol. 131, Iss. 6
Closed Access | Times Cited: 1
A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy
Ling Peng, Bao‐Dong Qin, Kui Xiao, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 65
Page 1 - Next Page

Scroll to top